Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-22 4:59 pm Unchanged | 2024-03-21 | 13D | Compass Therapeutics, Inc. CMPX | ORBIMED ADVISORS LLC | 18,791,422 13.700% | 0 (Unchanged) | Filing History |
| 2024-03-21 4:31 pm Unchanged | 2024-03-19 | 13D | Adicet Bio, Inc. ACET | ORBIMED ADVISORS LLC | 9,772,598 11.900% | 0 (Unchanged) | Filing History |
| 2024-03-08 4:34 pm Sale | 2024-03-06 | 13D | NextCure, Inc. NXTC | ORBIMED ADVISORS LLC | 1,268,013 4.500% | -1,443,000 (-53.23%) | Filing History |
| 2024-02-21 4:11 pm Unchanged | 2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.100% | 0 (Unchanged) | Filing History |
| 2024-02-14 7:45 pm Sale | 2023-12-31 | 13G | ALX Oncology Holdings Inc. ALXO | ORBIMED ADVISORS LLC | 2,255,000 4.500% | -11,000 (-0.49%) | Filing History |
| 2024-02-14 7:41 pm Purchase | 2023-12-31 | 13G | InspireMD, Inc. NSPR | ORBIMED ADVISORS LLC | 2,133,405 9.900% | 2,133,405 (New Position) | Filing History |
| 2024-02-14 7:36 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 11,494,437 6.700% | 1,165,788 (+11.29%) | Filing History |
| 2024-02-14 7:31 pm Purchase | 2023-12-31 | 13G | Verastem, Inc. VSTM | ORBIMED ADVISORS LLC | 1,529,115 6.100% | 1,529,115 (New Position) | Filing History |
| 2024-02-14 7:28 pm Sale | 2023-12-31 | 13G | SI-BONE, Inc. SIBN | ORBIMED ADVISORS LLC | 2,144,631 5.300% | -1,056,469 (-33.00%) | Filing History |
| 2024-02-14 7:21 pm Purchase | 2023-12-31 | 13G | Scholar Rock Holding Corporation SRRK | ORBIMED ADVISORS LLC | 2,960,000 4.100% | 2,960,000 (New Position) | Filing History |
| 2024-02-14 7:11 pm Sale | 2023-12-31 | 13G | Protara Therapeutics, Inc. TARA | ORBIMED ADVISORS LLC | 0 0.000% | -671,741 (Position Closed) | Filing History |
| 2024-02-14 7:00 pm Sale | 2023-12-31 | 13G | NeuroPace, Inc. NPCE | ORBIMED ADVISORS LLC | 4,003,967 15.200% | -8,314 (-0.21%) | Filing History |
| 2024-02-14 6:55 pm Sale | 2023-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | ORBIMED ADVISORS LLC | 0 0.000% | -7,082,837 (Position Closed) | Filing History |
| 2024-02-14 6:51 pm Sale | 2023-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 0 0.000% | -10,378,591 (Position Closed) | Filing History |
| 2024-02-14 6:47 pm Sale | 2023-12-31 | 13G | Kezar Life Sciences, Inc. KZR | ORBIMED ADVISORS LLC | 192,700 2.700% | -156,812 (-44.87%) | Filing History |
| 2024-02-14 6:42 pm Purchase | 2023-12-31 | 13G | Elevation Oncology, Inc. ELEV | ORBIMED ADVISORS LLC | 3,000,000 6.800% | 3,000,000 (New Position) | Filing History |
| 2024-02-14 6:36 pm Sale | 2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 1,667,360 2.500% | -1,529,516 (-47.84%) | Filing History |
| 2024-02-14 6:30 pm Sale | 2023-12-31 | 13G | Applied Therapeutics, Inc. APLT | ORBIMED ADVISORS LLC | 0 0.000% | -7,300,921 (Position Closed) | Filing History |
| 2024-02-05 4:48 pm Unchanged | 2024-02-05 | 13D | CalciMedica, Inc. CALC | ORBIMED ADVISORS LLC | 297,380 2.900% | 0 (Unchanged) | Filing History |
| 2024-02-05 4:42 pm Purchase | 2024-01-30 | 13D | ArriVent BioPharma, Inc. Common Stock AVBP | ORBIMED ADVISORS LLC | 3,027,328 9.100% | 3,027,328 (New Position) | Filing History |